CVS Health Valuation
Is CVS * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CVS * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CVS * (MX$1224.99) is trading below our estimate of fair value (MX$3730.59)
Significantly Below Fair Value: CVS * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CVS *?
Key metric: As CVS * is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is CVS *'s PE Ratio? | |
|---|---|
| PE Ratio | 14.8x |
| Earnings | US$5.02b |
| Market Cap | US$75.61b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.4x |
| Enterprise Value/EBITDA | 10.5x |
| PEG Ratio | 0.8x |
Price to Earnings Ratio vs Peers
How does CVS *'s PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 28.7x | ||
CI Cigna Group | 30.7x | 24.4% | US$92.6b |
LH Labcorp Holdings | 45.8x | 20.6% | US$20.2b |
DGX Quest Diagnostics | 21.6x | 11.7% | US$18.1b |
DVA DaVita | 16.6x | 4.3% | US$13.7b |
CVS * CVS Health | 14.8x | 18.0% | Mex$75.6b |
Price-To-Earnings vs Peers: CVS * is good value based on its Price-To-Earnings Ratio (14.8x) compared to the peer average (28.7x).
Price to Earnings Ratio vs Industry
How does CVS *'s PE Ratio compare vs other companies in the Global Healthcare Industry?
| 12 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 12 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: CVS * is good value based on its Price-To-Earnings Ratio (14.8x) compared to the Global Healthcare industry average (20.9x).
Price to Earnings Ratio vs Fair Ratio
What is CVS *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 14.8x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CVS *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | Mex$1,224.99 | Mex$1,388.31 +13.3% | 13.5% | Mex$1,889.06 | Mex$1,157.81 | n/a | 25 |
| Nov ’25 | Mex$1,132.00 | Mex$1,377.00 +21.6% | 14.4% | Mex$1,843.79 | Mex$1,169.72 | n/a | 25 |
| Oct ’25 | Mex$1,232.14 | Mex$1,297.97 +5.3% | 14.0% | Mex$1,798.03 | Mex$1,140.69 | n/a | 25 |
| Sep ’25 | Mex$1,127.00 | Mex$1,283.10 +13.9% | 13.0% | Mex$1,774.14 | Mex$1,125.53 | n/a | 25 |
| Aug ’25 | Mex$1,110.03 | Mex$1,270.20 +14.4% | 13.1% | Mex$1,743.86 | Mex$1,087.57 | n/a | 25 |
| Jul ’25 | Mex$1,061.00 | Mex$1,272.06 +19.9% | 13.4% | Mex$1,712.14 | Mex$1,086.20 | n/a | 26 |
| Jun ’25 | Mex$999.75 | Mex$1,170.95 +17.1% | 13.5% | Mex$1,577.81 | Mex$1,000.98 | n/a | 26 |
| May ’25 | Mex$1,170.00 | Mex$1,441.22 +23.2% | 10.8% | Mex$1,718.80 | Mex$1,021.07 | n/a | 26 |
| Apr ’25 | Mex$1,323.67 | Mex$1,492.25 +12.7% | 7.5% | Mex$1,718.14 | Mex$1,284.44 | n/a | 26 |
| Mar ’25 | Mex$1,260.00 | Mex$1,529.96 +21.4% | 7.0% | Mex$1,755.94 | Mex$1,312.70 | n/a | 25 |
| Feb ’25 | Mex$1,261.50 | Mex$1,550.20 +22.9% | 7.4% | Mex$1,778.25 | Mex$1,367.89 | n/a | 24 |
| Jan ’25 | Mex$1,334.20 | Mex$1,502.00 +12.6% | 8.6% | Mex$1,766.81 | Mex$1,291.13 | n/a | 24 |
| Dec ’24 | Mex$1,175.00 | Mex$1,511.98 +28.7% | 9.2% | Mex$1,788.74 | Mex$1,307.15 | n/a | 23 |
| Nov ’24 | Mex$1,210.00 | Mex$1,606.48 +32.8% | 10.4% | Mex$1,959.35 | Mex$1,353.73 | Mex$1,132.00 | 23 |
| Oct ’24 | Mex$1,229.00 | Mex$1,603.68 +30.5% | 10.3% | Mex$1,928.49 | Mex$1,332.41 | Mex$1,232.14 | 24 |
| Sep ’24 | Mex$1,118.00 | Mex$1,577.63 +41.1% | 9.8% | Mex$1,880.04 | Mex$1,298.94 | Mex$1,127.00 | 24 |
| Aug ’24 | Mex$1,248.00 | Mex$1,590.02 +27.4% | 12.2% | Mex$2,023.36 | Mex$1,214.01 | Mex$1,110.03 | 23 |
| Jul ’24 | Mex$1,188.00 | Mex$1,699.72 +43.1% | 16.6% | Mex$2,447.02 | Mex$1,300.51 | Mex$1,061.00 | 24 |
| Jun ’24 | Mex$1,213.00 | Mex$1,769.74 +45.9% | 16.6% | Mex$2,525.35 | Mex$1,342.14 | Mex$999.75 | 23 |
| May ’24 | Mex$1,315.03 | Mex$1,957.48 +48.9% | 13.3% | Mex$2,563.79 | Mex$1,541.86 | Mex$1,170.00 | 22 |
| Apr ’24 | Mex$1,339.00 | Mex$2,048.77 +53.0% | 10.0% | Mex$2,587.24 | Mex$1,718.80 | Mex$1,323.67 | 21 |
| Mar ’24 | Mex$1,489.84 | Mex$2,095.52 +40.7% | 9.4% | Mex$2,627.50 | Mex$1,745.54 | Mex$1,260.00 | 21 |
| Feb ’24 | Mex$1,631.31 | Mex$2,208.17 +35.4% | 6.5% | Mex$2,456.17 | Mex$1,889.36 | Mex$1,261.50 | 23 |
| Jan ’24 | Mex$1,755.10 | Mex$2,324.26 +32.4% | 4.9% | Mex$2,552.07 | Mex$2,080.92 | Mex$1,334.20 | 23 |
| Dec ’23 | Mex$1,947.00 | Mex$2,295.57 +17.9% | 4.9% | Mex$2,515.94 | Mex$2,051.46 | Mex$1,175.00 | 23 |
| Nov ’23 | Mex$1,850.00 | Mex$2,394.55 +29.4% | 5.8% | Mex$2,606.94 | Mex$2,005.34 | Mex$1,210.00 | 23 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Médica Sur. de
Mex$3.3b
Operates as a healthcare hospital in Mexico.
MEDICA B
Mex$32.00
7D
11.0%
1Y
-23.4%
Teladoc Health
US$2.1b
Provides virtual healthcare services worldwide.
TDOC *
US$239.00
7D
30.6%
1Y
-22.4%
ZimVie
US$186.2m
Develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide.
ZIMV *
US$230.00
7D
0%
1Y
n/a